Clinical Trial Update: Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial updating efficacy and safety of CT-P6 in HER2-positive breast cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CT-P6 (trastuzumab biosimilar)

Snippet

Sponsor: Celltrion | Conditions: HER2-positive Carcinoma of Breast | Phase 3 | Status: COMPLETED | Results posted: 2019-10-29